search
Back to results

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

Primary Purpose

Jaw Fractures, Infection

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Antibiotic treatment (Unasyn or Cleocin)
Antibiotic treatment (Augmentin or Cleocin)
Control Group
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Jaw Fractures focused on measuring Infection, Jaw fracture

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All mandible fracture patients planned for Open Reduction and Internal Fixation (ORIF)

Exclusion Criteria:

  • Age - < 18 years
  • Pregnancy
  • Fracture Site - closed / non-dentate eg. Condylar neck, edentulous
  • Soft Tissue Injury - > Grade 4 (GSW)
  • Allergic to all study drugs
  • Medical Problems

    1. Diabetes - Hb A1C > 10
    2. Immunologic compromise
    3. On Chemotherapy
  • Interval - Injury to Surgery - > 10days
  • Already receiving antibiotics for

    1. Another wound eg. Open fracture prophylaxis
    2. Documented / suspected infection
  • Inability to provide informed consent.

Sites / Locations

  • Memorial Hermann HospitalRecruiting
  • Th University of Texas Health Science Center at HoustonRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment

Control

Arm Description

Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.

Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.

Outcomes

Primary Outcome Measures

Evidence of infection as measured by presence of persistent swelling,
Evidence of infection as measured by presence of persistent swelling,
Evidence of infection as measured by presence of persistent swelling,
Evidence of infection as measured by presence of fever
Evidence of infection as measured by presence of fever
Evidence of infection as measured by presence of fever
Evidence of infection as measured by presence of recurrent swelling
Evidence of infection as measured by presence of recurrent swelling
Evidence of infection as measured by presence of recurrent swelling
Evidence of infection as measured by presence of erythema
Evidence of infection as measured by presence of erythema
Evidence of infection as measured by presence of erythema
Evidence of infection as measured by presence of purulent discharge
Evidence of infection as measured by presence of purulent discharge
Evidence of infection as measured by presence of purulent discharge

Secondary Outcome Measures

No evidence of infection as measured by absence of persistent swelling
No evidence of infection as measured by absence of persistent swelling
No evidence of infection as measured by absence of persistent swelling
No evidence of infection as measured by absence of fever
No evidence of infection as measured by absence of fever
No evidence of infection as measured by absence of fever
No evidence of infection as measured by absence of recurrent swelling
No evidence of infection as measured by absence of recurrent swelling
No evidence of infection as measured by absence of recurrent swelling
No evidence of infection as measured by absence of erythema
No evidence of infection as measured by absence of erythema
No evidence of infection as measured by absence of erythema
No evidence of infection as measured by absence of purulent discharge
No evidence of infection as measured by absence of purulent discharge
No evidence of infection as measured by absence of purulent discharge

Full Information

First Posted
December 9, 2019
Last Updated
November 15, 2020
Sponsor
The University of Texas Health Science Center, Houston
search

1. Study Identification

Unique Protocol Identification Number
NCT04198129
Brief Title
The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures
Official Title
The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 1, 2020 (Actual)
Primary Completion Date
January 1, 2022 (Anticipated)
Study Completion Date
March 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to evaluate if postoperative antibiotic use in patients with mandible trauma reduce the risk of postoperative infections and does the benefit differ based on severity, soft tissue loss, other concomitant injuries, and medical problems
Detailed Description
The purpose of this study is to evaluate the use of antibiotics postoperatively in non-infected mandible fractures compared to the lack of postoperative antibiotics in the same population. The first outcome measure is infection. Evidence of infection includes persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. The second outcome measure is no infection. Absence of persistent swelling, fever, recurrent swelling, erythema, and purulent discharge. Outcome measures will be assessed on follow-up visits: post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks. If the subject presents with any of the above mentioned symptoms during the 8 week post-op period, the subject will be considered positive for infection. Prospective randomized trial: Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care. Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days. The patient will follow up post op week 1, post op week 3, and post op week 6-8. Latest follow-up is up to 8 weeks. Patients will be monitored for any complications, including reaction to IV and oral antibiotics. Patient will assessed after the one-time post-op IV antibiotic dose and during their follow-up visits at weeks 1, 3, and 6-8.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Jaw Fractures, Infection
Keywords
Infection, Jaw fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
174 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies), then the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days (Amoxicillin and Clavulanic acid which is clinically interchangeable with Unasyn), or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies). If the patient is discharged home prior to completing 7 days of oral antibiotic therapy, patient will receive prescription to finish the remaining doses of antibiotics for a total period of 7 days.
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care.
Intervention Type
Drug
Intervention Name(s)
Antibiotic treatment (Unasyn or Cleocin)
Other Intervention Name(s)
UNasyn is the trade name and the genric name is Ampicillin and Sub lactam. Cleocin is a trade name and the generic name is clindamycin.
Intervention Description
Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
Intervention Type
Drug
Intervention Name(s)
Antibiotic treatment (Augmentin or Cleocin)
Other Intervention Name(s)
Augmentin is the trade name and the generic is Amoxicillin Clavulinate or clavulinic acid. Cleocin is the trade name and the generic is clindamycin.
Intervention Description
the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Intervention Type
Other
Intervention Name(s)
Control Group
Intervention Description
Control group will not receive any postoperative antibiotics other than what is accepted as preoperative prophylactic antibiotics as per current standards of care
Primary Outcome Measure Information:
Title
Evidence of infection as measured by presence of persistent swelling,
Time Frame
post treatment week1
Title
Evidence of infection as measured by presence of persistent swelling,
Time Frame
post treatment week 3
Title
Evidence of infection as measured by presence of persistent swelling,
Time Frame
post treatment week 6-8
Title
Evidence of infection as measured by presence of fever
Time Frame
post treatment week 1
Title
Evidence of infection as measured by presence of fever
Time Frame
post treatment week 3
Title
Evidence of infection as measured by presence of fever
Time Frame
post treatment week 6-8
Title
Evidence of infection as measured by presence of recurrent swelling
Time Frame
post treatment week 1
Title
Evidence of infection as measured by presence of recurrent swelling
Time Frame
post treatment week 3
Title
Evidence of infection as measured by presence of recurrent swelling
Time Frame
post treatment week 6-8
Title
Evidence of infection as measured by presence of erythema
Time Frame
post treatment week 1
Title
Evidence of infection as measured by presence of erythema
Time Frame
post treatment week 3
Title
Evidence of infection as measured by presence of erythema
Time Frame
post treatment week 6-8
Title
Evidence of infection as measured by presence of purulent discharge
Time Frame
post treatment week 1
Title
Evidence of infection as measured by presence of purulent discharge
Time Frame
post treatment week 3
Title
Evidence of infection as measured by presence of purulent discharge
Time Frame
post treatment week 6-8
Secondary Outcome Measure Information:
Title
No evidence of infection as measured by absence of persistent swelling
Time Frame
post treatment week 1
Title
No evidence of infection as measured by absence of persistent swelling
Time Frame
post treatment week 3
Title
No evidence of infection as measured by absence of persistent swelling
Time Frame
post treatment week 6-8
Title
No evidence of infection as measured by absence of fever
Time Frame
post treatment week 1
Title
No evidence of infection as measured by absence of fever
Time Frame
post treatment week 3
Title
No evidence of infection as measured by absence of fever
Time Frame
post treatment week 6-8
Title
No evidence of infection as measured by absence of recurrent swelling
Time Frame
post treatment week 1
Title
No evidence of infection as measured by absence of recurrent swelling
Time Frame
post treatment week 3
Title
No evidence of infection as measured by absence of recurrent swelling
Time Frame
post treatment week 6-8
Title
No evidence of infection as measured by absence of erythema
Time Frame
post treatment week 1
Title
No evidence of infection as measured by absence of erythema
Time Frame
post treatment week 3
Title
No evidence of infection as measured by absence of erythema
Time Frame
post treatment week 6-8
Title
No evidence of infection as measured by absence of purulent discharge
Time Frame
post treatment week 1
Title
No evidence of infection as measured by absence of purulent discharge
Time Frame
post treatment week 3
Title
No evidence of infection as measured by absence of purulent discharge
Time Frame
post treatment week 6-8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All mandible fracture patients planned for Open Reduction and Internal Fixation (ORIF) Exclusion Criteria: Age - < 18 years Pregnancy Fracture Site - closed / non-dentate eg. Condylar neck, edentulous Soft Tissue Injury - > Grade 4 (GSW) Allergic to all study drugs Medical Problems Diabetes - Hb A1C > 10 Immunologic compromise On Chemotherapy Interval - Injury to Surgery - > 10days Already receiving antibiotics for Another wound eg. Open fracture prophylaxis Documented / suspected infection Inability to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nagi Demian, DDS/MD
Phone
713-500-5082
Email
Nagi.Demian@uth.tmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Donna Martinez
Phone
713-500-5082
Email
Donna.M.Martinez@uth.tmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nagi Demian, DDS/MD
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Memorial Hermann Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Name
Th University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nagi Demian, DDS, MD
Phone
713-500-5082
Email
Nagi.Demian@uth.tmc.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Evaluation of Postoperative Antibiotics in Non-Infected Mandible Fractures

We'll reach out to this number within 24 hrs